Medium chain triglyceride compositions

1. A method for providing ketones and/or C10 fatty acids to a subject in need thereof, the method comprising administering to the subject a composition comprising medium-chain triglycerides (MCTs) comprising a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10),

wherein a ratio of the MCT-C8 to the MCT-C10 is from 10:90 to 90:10 (mol/mol), and wherein the combined amount of the MCT-C8 and the MCT-C10 is at least 50 mol % of the MCTs in the composition,

wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.

2. The method according to claim 1 , wherein the ketones comprise at least one of β-hydroxy butyrate or aceto acetate.

3. The method according to claim 1 wherein exposure of the subject to the ketones following the administering of the composition is greater than following an administration of a composition comprising the following MCT species:

Species in MCT(mixC8/C10 60:40)

Mole %

MCT-C8

22%

MCT-C10

10%

MCT(mix C8/C10) 2:1

34%

MCT(mix C8/C10) 1:2

34%

wherein mixC8/10 2:1 is a MCT comprising two fatty acid moieties having 8 carbon atoms and one fatty acid moiety having 10 carbon atoms, and

wherein mixC8/10 1:2 is a MCT comprising one fatty acid moiety having 8 carbon atoms and two fatty acid moieties having 10 carbon atoms.

4. The method according to claim 1 , wherein the individual has a disorder selected from the group consisting of a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders, bipolar disorder, schizophrenia, epilepsy, and combinations thereof.

5. The method according to claim 1 , wherein the composition is administered enterally.

6. The method according to claim 1 , wherein the composition is in the form of a food stuff or a feed.

7. The method according to claim 1 , wherein the composition is in a form selected from the group consisting of a medical food, a tube feed, a nutritional composition and a nutritional supplement.

8. The method according to claim 1 , wherein the composition is in a form selected from the group consisting of a beverage, mayonnaise, salad dressing, margarine, low fat spread, dairy product, cheese spread, processed cheese, dairy dessert, flavoured milk, cream, fermented milk product, cheese, butter, condensed milk product, ice cream mix, soya product, pasteurised liquid egg, bakery product, confectionary product, confectionary bar, chocolate bar, high fat bar, liquid emulsion, spray-dried powder, freeze-dried powder, UHT pudding, pasteurised pudding, gel, jelly, yoghurt, and a food with a fat-based or water-containing filling.

9. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is from 20:80 to 85:15 (mol/mol).

10. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is from 50:50 to 67:33 (mol/mol).

11. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is from 55:45 to 65:35 (mol/mol).

12. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is from 58:42 to 62:38 (mol/mol).

13. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is about 60:40 (mol/mol).

14. The method according to claim 1 , wherein the combined amount of the MCT-C8 and the MCT-C10 is at least 90 mol % of the MCTs in the composition.

15. The method according to claim 1 , wherein the three fatty acid moieties each with 8 carbon atoms are octanoic acid moieties, and/or the three fatty acid moieties each with 10 carbon atoms are decanoic acid moieties.

16. The method according to claim 1 , wherein the subject has a brain energy deficiency condition.

17. The method according to claim 1 , wherein the composition further comprises an agent that promotes or sustains neurologic health or enhance cognitive function, and the agent is selected from the group consisting of vitamins, choline, phosphatidylserine, alpha-lipoic acid, CoQ10, acetyl-L-carintine, herbal extracts, omega-3 or omega-6 polyunsaturated fatty acids, aliphatic ester, fish oil extracts, and combinations thereof.